Summary

MTRR A66G determines how efficiently you recycle vitamin B12 into its active methylcobalamin form — the cofactor that keeps homocysteine clearance running. Clinically mild alone, but stacks with MTHFR variants to create compound methylation bottlenecks, and becomes genuinely important when B12 status is marginal.

Genotype spectrum

AA (Wild type)

Efficient B12 utilisation. Your MTR stays active longer between MTRR reactivation cycles.

AG (Heterozygous)

This is the most common genotype globally. Clinically silent for most people with adequate B12 intake.

GG (Homozygous)

Your intervention target is clear and specific: B12 form and adequacy. The gap between cyanocobalamin and methylcobalamin matters more for you than for AA carriers.

Practical takeaway

For GG Carriers (Moderate Attention)

Start here:
• Methylcobalamin: 1000 mcg/day sublingual. This is the specific B12 form that bypasses the MTRR bottleneck. Sublingual absorption avoids GI tract variability.
• Riboflavin (B2): 1.6 mg/day. MTRR uses FMN/FAD cofactors (same as MTHFR). Supports both enzymes.
• B12-rich foods: Prioritise liver, shellfish (clams, mussels), sardines, eggs, dairy. If vegan/vegetarian, supplementation is non-negotiable — not optional, not "if you feel like it."

Test (recommended, not mandatory):
• Serum B12: Baseline. But be aware — serum B12 can be "normal" while functional B12 is low (functional B12 deficiency). This is MORE likely with MTRR GG because you're recycling B12 less efficiently.
• Methylmalonic acid (MMA): This is the functional B12 marker. If MMA >0.4 μmol/L, your intracellular B12 is insufficient regardless of what serum B12 says. Request this alongside serum B12.
• Homocysteine: Baseline. If >12 μmol/L, follow the full methylation support protocol.

If stacking with MTHFR:
• MTHFR C677T TT + MTRR GG = dual methylation bottleneck. Follow the full mthfr_c677t protocol: methylfolate + methylcobalamin + riboflavin + B6.
• MTHFR C677T CT + MTRR GG = moderate compound load. Methylcobalamin + riboflavin + folate-rich diet.

What "working" looks like:
• MMA normalises (<0.4 μmol/L) within 8-12 weeks
• Homocysteine drops below 10 μmol/L (if elevated at baseline)
• Subjective: improved energy, cognitive clarity, mood stability (soft markers)

Expected response window: 8-12 weeks for biomarker normalisation. Subjective effects may be noticed earlier (4-6 weeks).
For AG Carriers (Low Priority Alone)
• Standard B12 intake from diet or a basic supplement covers it
• Methylcobalamin is a reasonable default B12 form (no downside vs cyanocobalamin, potential upside)
• Becomes more relevant if stacking with MTHFR or MTR variants
• If vegetarian/vegan: supplementation matters more for you than for AA carriers
For AA Carriers (No Specific Action)
• Efficient B12 recycling. Standard dietary B12 guidance.
• If vegetarian/vegan, you still need to supplement B12 — this genotype doesn't exempt you from dietary insufficiency.
Pregnancy-Specif

Evidence detail

What This Gene Does

MTRR (methionine synthase reductase) is the enzyme that reactivates methionine synthase (MTR) — the enzyme that converts homocysteine back to methionine. MTR needs methylcobalamin (the active methyl form of B12) to work, but methylcobalamin periodically gets oxidised and becomes inactive (cob(II)alamin). MTRR's job is to regenerate the active form. Without efficient MTRR, MTR gradually stalls, homocysteine builds up, and the methionine/SAM cycle slows.

Think of it as: MTR is the worker, methylcobalamin is the tool, and MTRR is the maintenance crew that keeps the tool sharp. A66G means your maintenance crew works a bit slower.

Mechanism

MTRR sits at a critical maintenance point in the methionine cycle:

1. MTR (methionine synthase) converts homocysteine → methionine using methylcobalamin (methyl-B12) as its cofactor.
2. Each catalytic cycle, methylcobalamin occasionally gets oxidised to cob(II)alamin — rendering MTR inactive.
3. MTRR reactivates MTR by reducing cob(II)alamin back to methylcob(I)alamin using SAM as the methyl donor and NADPH as the electron source. This requires both FMN and FAD cofactors (from riboflavin/B2).
4. The A66G variant (Ile22Met) sits in the FMN-binding domain, reducing the enzyme's affinity for MTR. The reactivation cycle takes longer.

Why this matters practically:

When MTRR is slow, MTR spends more time in its inactive state. This means:
• Homocysteine clearance slows (MTR is stalled, so homocysteine accumulates)
• Methionine production drops (less substrate for SAM synthesis)
• The effect is conditional on B12 status — with abundant methylcobalamin available, even reduced MTRR can keep up. When B12 is marginal, the bottleneck becomes rate-limiting.

The methylcobalamin bypass logic:

If you supply methylcobalamin directly (instead of cyanocobalamin or hydroxocobalamin), you're giving MTR an already-active cofactor. Even when the cofactor oxidises and MTRR is slow to recycle it, the surplus of active B12 partially compensates. This is why methylcobalamin is the recommended B12 form for GG carriers — you're not fixing MTRR, you're flooding the system with its end product.

The riboflavin connection (shared with MTHFR):

MTRR requires FMN and FAD — both derived from riboflavin (B2). This means riboflavin supplementation potentially benefits both MTHFR and MTRR function. If you carry both MTHFR C677T and MTRR A66G, riboflavin is pulling double duty.

MTRR A66G

Summary

Genotype spectrum

Practical takeaway

Evidence detail

Sources (12)